Domestic swine (n = 12 in each group) were randomized to daily treatment with the thromboxane A2 (TXA2) receptor antagonist BMS-180291 (group I), aspirin (group II), or no drug (group III) prior to prosthetic carotid graft implantation. Platelet and arterial wall receptor density were measured by equilibrium binding using 125I-BOP. At 6 weeks, means (s.e.m.) platelet receptor density (pmol/mg) had increased in groups I (3.3(0.6) versus 1.8(0.3); P<0.05) and II (2.6(0.6) versus 1.7(0.2); P<0.05), but not in group III (1.3(0.3) versus 1.2(0.2)). Aortic membrane TXA2 receptor density (fmol/mg) was significantly greater (P<0.05) in groups I (150(50)) and II (68(10)) compared with group III (39(6)). Chronic exposure to a TXA2 receptor antagonist or aspirin is associated with increased platelet and aortic receptor density in pigs. Published by Elsevier Science Ltd.
GrahamL.M.VincentC.K.BrothersT.E., Efficacy of antiplatelet agents in promoting patency and reducing anastomotic hyperplasia of endothelial cell seeded and unseeded e-PTFE grafts. Surgery Forum, 1988, 39, 348–350.
2.
BrothersT.E.VincentC.K.DarvishianD., Effects of duration of acetylsalicylic acid administration on patency and anastomotic hyperplasia of ePTFE grafts. American Society of Artificial Internal Organs Transactions, 1989, 35, 558–560.
3.
CahillP.D.SarrisG.E.CooperA.D., Inhibition of vein graft intimal thickening by eicosapentanoic acid: Reduced thromboxane production without change in lipoprotein levels or low-density lipoprotein receptor density. Journal of Vascular Surgery, 1988, 7, 108–118.
4.
HagenP.O.WangZ.G.MikatE.M.HackelD.B., Antiplatelet therapy reduces aortic intimal hyperplasia distal to small diameter vascular prostheses (PTFE) in nonhuman primates. Annals of Surgery, 1982, 195, 328–339.
5.
OblathR.W.BuckleyF.O.GreenR.M.SchwartzS.I.DeWeeseJ.A., Prevention of platelet aggregation and adherence to prosthetic vascular grafts by aspirin and dipyridamole. Surgery, 1978, 84, 37–44.
6.
ZammitM.KaplanS.SauvageL.R.MarcoeK.F.WuH.D., Aspirin therapy in small-caliber arterial prostheses: Long-term experimental observations. Journal of Vascular Surgery, 1984, 1, 839–851.
7.
ClowesA.W., The role of aspirin in enhancing arterial graft patency. Journal of Vascular Surgery, 1986, 3, 381–385.
8.
CargileM.NeymanS.L.HebelerR.E.AskinsR.O'LearyJ.P., Effect of selective thromboxane synthetase inhibitor on vein grafts. Southern Medical Journal, 1987, 80, 1355–1359.
9.
HansonS.R.HarkerL.A., Effect of dazoxiben on arterial graft thrombosis in the baboon. British Journal of Clinical Pharmacology, 1983, 15(Suppl 1), 57S–60S.
10.
McDanielM.D.HuntsmanW.T.MiettT.O.CronenwettJ.L., Effect of a selective thromboxane synthase inhibitor on arterial graft patency and platelet deposition in dogs. Archives of Surgery, 1987, 122, 887–892.
11.
GrahamL.M.BrothersT.E.DarvishianD., Effects of thromboxane synthetase inhibition on patency and anastomotic hyperplasia of vascular grafts. Journal of Surgical Research, 1989, 46, 611–615.
MaisD.E.SaussyD.L.ChaikhouniA., Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors. Journal of Pharmacology and Experimental Therapeutics, 1985, 233, 418–424.
14.
SaussyD.L.MaisD.E.BurchR.M.HalushkaP.V., Identification of a putative thromboxane A2/prostaglandin H2 receptor in human platelet membranes. Journal of Biological Chemistry, 1986, 261, 3025–3029.
15.
OgletreeM.L.HarrisD.N.SchumacherW.A.WebbM.L.MisraR.N., Pharmacological profile of BMS 180,291: A potent, long-acting, orally active thromboxane A2/prostaglandin endoperoxide receptor antagonist. Journal of Pharmacology and Experimental Therapeutics, 1993, 264, 570–578.
16.
MorinelliT.A.OatisJ.E.OkwuA., Characterization of an [125]I-labeled thromboxane A2/prostaglandin H2 receptor agonist. Journal of Pharmacology and Experimental Therapeutics, 1989, 251, 557–562.
17.
HanasakiK.NakanoT.AritaH., Receptor-mediated mitogenic effect of thromboxane A2 in vascular smooth muscle cells. Biochemical Pharmacology, 1990, 40, 2535–2542.
18.
IshimitsuT.VeharaY.IshiiM.IkedaT.MatsuokaH.SugimotoT., Thromboxane and vascular smooth muscle cell growth in genetically hypertensive rats. Hypertension, 1988, 12, 46–51.
19.
BushH.L.JakubowskiJ.A.HongS.L., Luminal release of prostacyclin and thromboxane A2 by arteries distal to small-caliber prosthetic grafts. Circulation, 1984, 70, 111–115.
20.
MerhiY.GuidoinR.ForestX., Fate of polyester arterial prostheses implanted as thoracoabdominal by-passes in dogs: Haematology, pathology, and biochemistry. Clinical and Investigative Medicine, 1988, 11, 403–416.
21.
LewinJ.SwedenborgJ.EgbergN.VesterqvistO.GreenK., Effect of acetyl salicylic acid on increased production of thromboxane after aortic graft surgery. European Journal of Vascular Surgery, 1989, 3, 213–218.
22.
VesterqvistO.GreenK.LewinJ.SwedenborgJ., Synthetic arterial grafts cause prolonged increase in the in vivo formation of thromboxane and prostacyclin in humans. Research in Experimental Medicine, 1987, 187, 175–184.
23.
BechF.R.CronenwettJ.L.McDanielM.D.OgletreeM.L.FreemanD.H., The effect of thromboxane receptor blockade versus thromboxane synthase inhition on canine arterial graft patency. Journal of Vascular Surgery, 1990, 12, 119–125.
